Related Experiment Video

Updated: Feb 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Research progress on the role of DDR1 in cancer and targeted therapy strategy

Xiaoying Guan1,2, Yajie Zhang3, Xiaoli Guan4

  • 1Pathology Department, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.

Neoplasma
|February 19, 2026
PubMed

Insights

Discoidin domain receptor 1 (DDR1), a collagen-activated kinase, drives solid tumor progression and chemoresistance. Targeting DDR1 with inhibitors or antibodies offers a promising new strategy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase implicated in solid tumor development.
  • DDR1 regulates critical cellular processes including adhesion, survival, proliferation, migration, and invasion.
  • Aberrant DDR1 activation is linked to cancer progression and therapeutic resistance.

Purpose of the Study:

  • To review the structural features of DDR1.
  • To elucidate DDR1's role in tumor progression and associated signaling pathways.
  • To explore DDR1's connection to chemotherapy resistance and evaluate therapeutic strategies.

Main Methods:

  • Literature review of DDR1 structure, function, and therapeutic targeting.
  • Analysis of signaling pathways regulated by DDR1 in cancer.
  • Examination of current research on DDR1 inhibitors and antibodies.

Main Results:

  • DDR1 structural characteristics and activation by collagen are detailed.
  • DDR1's significant role in promoting tumor cell migration, invasion, and survival is highlighted.
  • The association between DDR1 and resistance to chemotherapy is established.

Conclusions:

  • DDR1 is a critical mediator of tumor progression and chemoresistance.
  • Targeting DDR1 through inhibitors or antibodies presents a viable therapeutic avenue.
  • DDR1 inhibition strategies hold potential as novel cancer treatments.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K